Protalix Submits Marketing Authorization Application To EMA For PRX-102 For Fabry Disease Treatment
28/2 02:37
(RTTNews) - Protalix BioTherapeutics Inc. (PLX) and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., announced the submission of a Marketing Authorization Application or MAA via centralized procedure to the European Medicines Agency or EMA for pegunigal...